Cytomegalovirus infection after prophylactic valganciclovir therapy post-kidney transplantation: case reports.
This report describes three patients who developed cytomegalovirus infection 4 months after high-risk donor+/recipient-(D+/R-) kidney transplantation, despite treatment with valgancyclovir (VGCV) for 3 months at low dose (450 mg/d).
Department of Urology, Sakai Hospital Kinki University Faculty of Medicine, Sakai City, Japan. kams.nose@sakai.med.kindai.ac.jp
K
K
Nose
T
T
Oki
E
E
Banno
M
M
Nakagawa
K
K
Sugimoto
T
T
Nishioka
T
T
Akiyama
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D004334:Drug Administration Schedule; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D013997:Time Factors; D016896:Treatment Outcome; D000077562:Valganciclovir
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000077562:Valganciclovir; D015774:Ganciclovir